| ²é¿´: 423 | »Ø¸´: 2 | ||
| ¡¾ÐüÉͽð±Ò¡¿»Ø´ð±¾ÌûÎÊÌ⣬×÷Õ߻ƻÆ516½«ÔùËÍÄú 5 ¸ö½ð±Ò | ||
[ÇóÖú]
Blood ¹ØÓÚZUMA7Ñо¿½á¹û
|
||
|
Âé·³°ïæÕÒÒ»ÏÂÔÎÄ ·¢×ÔСľ³æIOS¿Í»§¶Ë |
» ²ÂÄãϲ»¶
ɽ¶«Ê¡ÃæÉÏÏîÄ¿ÏÞ¶îÆÀÉó
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤´óѧ070300 ѧ˶336Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
ÉúÎïѧ071000 329·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸»ªÖпƼ¼´óѧ071000£¬Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
ÉúÎïѧһ־Ը985£¬·ÖÊý349Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
ÉúÎïѧµ÷¼Á
ÒѾÓÐ4È˻ظ´
Çóµ÷¼ÁԺУÐÅÏ¢
ÒѾÓÐ4È˻ظ´
085600²ÄÁÏÓ뻯¹¤306
ÒѾÓÐ4È˻ظ´
286Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
328Çóµ÷¼Á£¬Ó¢ÓïÁù¼¶551£¬ÓпÆÑоÀú
ÒѾÓÐ9È˻ظ´
|
Blood. 2022 Nov 24;140(21):2248-2260Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma ·¢×ÔСľ³æIOS¿Í»§¶Ë |
2Â¥2024-01-23 10:21:49
3Â¥2024-01-23 10:22:09













»Ø¸´´ËÂ¥